Schering-Plough Establishes Brazilian Subsidiary

Article

Schering-Plough (Kenilworth, NJ, www.sch-plough.com) will establish Schering-Plough Produtos Farmaceuticos Limitada in Sao Paulo, Brazil, to market its core products.

Schering-Plough (Kenilworth, NJ, www.sch-plough.com) will establish Schering-Plough Produtos Farmaceuticos Limitada in Sao Paulo, Brazil, to market its core products. The company will also restructure its agreement (originally formed in 1991) with Brazil-based drug manufacturer Mantefarma, now to be known as Mantecorp, in an effort to increase Schering’s presence in Latin America. Schering-Plough Produtos Farmaceuticos Limitada will commercialize specialty care products, including hepatitis C treatment PegIntron (peginterferon alfa-2b) and cancer-fighting drugs Temodal (temozolomide) and Caelyx (pegylated liposomal doxorubicin HCI).

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Mike Schaefers Simtra BioPharma Solutions, Shiva Khalafpour MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany
Chris Hagen, SCIEX
Daniel Fischer, Tevard
Junevity Co-founder & CEO, John Hoekman, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.